- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lymphomas | Clinical
Zain Evaluates Studies Offering Improvement in R/R DLBCL Survival
October 06, 2022
During a case-based rountable event, Jasmine Zain, MD of City of Hope, discussed the case of a 79-year-old patients with relapsed or refractory diffuse large B-cell lymphoma.
How Will New Immunotherapies Fit Into the Treatment Landscape of Follicular Lymphoma?
October 04, 2022
Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.
FDA Approval Sought for Denileukin Diftitox in Persistent or Recurrent CTCL
October 03, 2022
Results from the phase 3 Study 302 of denileukin diftitoc in patients with persistent of recurrent cutaneous T-cell lymphoma led to the submission of a biologics license application for the drug.
CD20/CD3 Bispecific Antibodies Can Revolutionize B-Cell Lymphoma Therapy
October 03, 2022
The bispecific antibodies for B-cell lymphoma that are under development target CD20, and they have a second receptor that targets CD3, which is present on vector T cells, according to Loretta J. Nastoupil, MD.
Research Shows Promise for Directing Later Lines of Therapy for Hodgkin Lymphoma
October 02, 2022
Research now is addressing how subsequent therapies can meet needs of patients with Hodgkin lymphoma who progress after early lines of treatment.
Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma
September 30, 2022
As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.
Emerging EZH 1/2 Inhibitors Demonstrate Single-Agent Efficacy in R/R PTCL
September 30, 2022
Novel targets continue to emerge through clinical trials in peripheral T0cell lymphoma, in particular EZH 1 and EZH 2 inhibitors, which have strong single-agent efficacy.
Many Challenges, Opportunities for CAR T-Cell Therapies in Lymphoma
September 30, 2022
Sattva S. Neelapu, MD will discuss chimeric antigen receptor T-cell therapy will in lymphoma iduring a session at the SOHO 2022 Annual Meeting.
Novel Agents Gain Ground as CTCL Treatment Landscape Evolves
September 30, 2022
Novel therapies for cutaneous T-cell lymphoma novel therapies for this patient population are helping to create straightforward management strategies.
Next Generation Novel Agents for Aggressive B-Cell Lymphoma
September 28, 2022
A SOHO 2022 presentation by Jason Westin, MD will focus on t on 2 main categories of novel agents that manipulate the immune system to better target aggressive lymphomas.